Glucaric acid is a lipid of Fatty Acyls (FA) class. Glucaric acid is associated with abnormalities such as Consumption-archaic term for TB and furuncle. The involved functions are known as Oxidation, Mutation, Process, Cell Growth and Anabolism. Glucaric acid often locates in BL21, Clone and host. The associated genes with Glucaric acid are MIOX gene, ISYNA1 gene, Genome and Candidate Disease Gene. The related experimental models are Knock-out.
To understand associated biological information of Glucaric acid, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Glucaric acid is suspected in and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Glucaric acid
Lipid pathways are not clear in current pathway databases. We organized associated pathways with Glucaric acid through full-text articles, including metabolic pathways or pathways of biological mechanisms.
Pathway name | Related literatures |
---|
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Gene | Cross reference | Weighted score | Related literatures |
---|
Knock-out are used in the study 'Evolution-guided optimization of biosynthetic pathways.' (Raman S et al., 2014).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Khaw BA et al. | Avidity of technetium 99m glucarate for the necrotic myocardium: in vivo and in vitro assessment. | 1997 Jul-Aug | J Nucl Cardiol | pmid:9278874 |
pmid:9278881 | ||||
Hildebrandt AG et al. | Evaluation of in vivo parameters of drug metabolizing enzyme activity in man after administration of clemastine, phenobarbital or placebo. | 1975 | Eur. J. Clin. Pharmacol. | pmid:9297 |
Cynke E | [Parenteral iron replacement]. | 1997 | Praxis (Bern 1994) | pmid:9312810 |
Furuno K et al. | Effect of D-Glucarates on basic antibiotic-induced renal damage in rats. | 1976 | J. Antibiot. | pmid:931801 |
Sunder-Plassmann G and Hörl WH | Safety aspects of parenteral iron in patients with end-stage renal disease. | 1997 | Drug Saf | pmid:9352960 |
Cazzola M | Recombinant human erythropoietin to assist autologous blood donation by patients with anemia. | 1997 | J. Lab. Clin. Med. | pmid:9358072 |
Sandle LN et al. | Indirect evidence for hepatic induction in patients with cholesterol gallstones. | 1997 | Biochem. Soc. Trans. | pmid:9388642 |
al-Hawas F et al. | Use of i.v. iron saccharate in haemodialysis patients not responding to oral iron and erythropoietin. | 1997 | Nephrol. Dial. Transplant. | pmid:9430909 |
Kuramitsu Y et al. | A new anti-metastatic drug, ND-2001, inhibits lung metastases in rat hepatoma cells by suppressing haptotaxis of tumor cells toward laminin. | 1998 | Anticancer Drugs | pmid:9491797 |